Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ: VYGR). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980. The investigation concerns whether Voyager and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On October 12, 2020, Voyager issued a press release disclosing that it “has received feedback from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington’s disease.” Specifically, Voyager advised investors that it “has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.” On this news, Voyager’s stock price fell sharply during intraday trading on October 13, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.org 888-476-6529 ext. 7980
Shares of the clinical-stage gene therapy company Voyager Therapeutics (NASDAQ: VYGR) dropped by as much as 11% in pre-market trading Tuesday morning. The biotech's shares are responding negatively to a regulatory delay for its Huntington's disease candidate, VY-HTT01. After market close yesterday, Voyager announced that the Food and Drug Administration placed a clinical hold on the experimental gene therapy pending the resolution of certain chemistry, manufacturing, and controls (CMC) matters.